August 1, 2024
AbstractThe development of novel therapeutic agents has become an imperative focus in the biomedical field, particularly for conditions lacking fully effective treatment options. Recent preclinical data published in the Proceedings of the National Academy of Sciences (PNAS) revealed encouraging findings for PIPE-307, an M1 receptor antagonist currently in development by Contineum Therapeutics, Inc. This article provides an extensive analysis of these findings and their implications for treatment strategies in Relapse-Remitting Multiple Sclerosis (RRMS). Relapse-Remitting Multiple Sclerosis (RRMS) is a chronic, inflammatory, demyelinating condition of the central nervous system characterized by unpredictable...
June 25, 2024
Sarah Boyce Appointed to Contineum Therapeutics' Board of Directors: Strengthening the Clinical Stage Biopharmaceutical Company's Drug Development StrategiesIn recent news, Contineum Therapeutics, a clinical stage biopharmaceutical company focused on the discovery and development of novel, oral small molecule therapies targeting biological pathways associated with specific clinical impairments, has announced the appointment of Sarah Boyce to their Board of Directors. Boyce currently serves as the President and Chief Executive Officer of Avidity Biosciences, a biotech company listed under Nasdaq as RNA.Contineum Therapeutics aims to combat various neuroscience, inflammation, and immunology (NIandI) indication...
June 24, 2024
'Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors'SAN DIEGO ?? Contineum Therapeutics, Inc. (Nasdaq: CTNM), a forward-thinking clinical stage biopharmaceutical company, has further solidified its executive leadership through the strategic addition of Sarah Boyce to its Board of Directors. Underlying this significant appointment is Contineum Therapeutics? commitment to revolutionizing the treatment landscape within the realms of neuroscience, inflammation, and immunology (NIandI) through the development of cutting-edge, oral small molecule therapies.Sarah Boyce, who currently serves as the President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), brings...
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
